^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Anaplastic Astrocytoma

Related cancers:
1d
Extracellular vesicles-mediated communication between glioblastoma and astrocytes promotes pro-tumorigenic activation. (PubMed, Med Oncol)
The results demonstrated that GBM-derived EVs significantly contribute to astrocyte phenotypic alterations associated with invasion and metastasis. These findings highlight the importance of EV-mediated intercellular communication in GBM progression and suggest further in vivo studies to elucidate their role in central nervous system invasion.
Journal
|
TGM2 (Transglutaminase 2)
4d
Trial suspension
|
IDH wild-type
|
Keytruda (pembrolizumab)
9d
Discovery of the MELK-Nucleostemin Axis in Glioblastoma: Implications for p53 Regulation and Tumor Progression. (PubMed, J Microbiol Biotechnol)
These findings define a previously unrecognized MELK-NS-p53 signaling axis that links kinase activity to the regulation of the cell cycle. Our fundings provide mechanistic insights into glioblastoma pathogenesis and suggest that targeting the MELK-NS pathway may be a potential therapeutic strategy for high-grade gliomas.
Journal
|
MELK (Maternal Embryonic Leucine Zipper Kinase) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
10d
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) (clinicaltrials.gov)
P3, N=365, Recruiting, Nuvation Bio Inc. | Phase classification: P2 --> P3 | N=125 --> 365 | Trial completion date: Mar 2028 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2028
Phase classification • Enrollment change • Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
|
IDH1 mutation • IDH1 R132
|
temozolomide • safusidenib (DS-1001)
15d
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) (clinicaltrials.gov)
P1, N=1, Terminated, University of Alabama at Birmingham | N=12 --> 1 | Trial completion date: Aug 2027 --> Mar 2025 | Enrolling by invitation --> Terminated | Trial primary completion date: Aug 2026 --> Mar 2025; Not enough eligible participants to enroll.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
15d
Radiation-induced sarcoma after glioma resection in patients with Li-Fraumeni syndrome: illustrative cases. (PubMed, J Neurosurg Case Lessons)
These cases represent the first definitive report of cranial RIS following glioma chemoradiation therapy in patients with LFS. The short latency and aggressive nature of these tumors at the irradiated site highlight the need for proactive follow-up in patients with LFS after chemoradiation therapy to screen for RIS and improve outcomes through timely intervention. https://thejns.org/doi/10.3171/CASE25588.
Journal
|
TP53 (Tumor protein P53) • DRD (DNA Repair Deficiency)
|
TP53 mutation • DDR
|
temozolomide
18d
Pediatric High-Grade Astrocytoma With Piloid Features: A Comprehensive Literature Review. (PubMed, Pediatr Blood Cancer)
This review did not identify definitive clinical or histomolecular differences between pediatric and adult HGAP, underscoring the need for further comparative studies. Pediatric HGAP may represent an underrecognized diagnostic entity within the glioma spectrum, emphasizing the critical role of methylation profiling for accurate diagnosis and classification. Retrospective reclassification of histologically and molecularly ambiguous gliomas is warranted and may reveal additional cases. Larger pediatric cohorts are urgently needed to inform clinical management and refine prognostic stratification.
Review • Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
21d
Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma. (PubMed, Ann Clin Transl Neurol)
Histologic grade 4 astrocytomas with CDKN2A/B homozygous deletion confer the worst survival. Maximal or complete resection, as assessed on FLAIR images, is critical to improving outcomes.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
CDKN2A deletion
23d
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma (clinicaltrials.gov)
P2, N=25, Recruiting, Mayo Clinic | Trial completion date: Apr 2026 --> Jul 2028 | Trial primary completion date: Apr 2026 --> Jul 2028
Trial completion date • Trial primary completion date
24d
Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis (PubMed, Zh Vopr Neirokhir Im N N Burdenko)
Original method based on marker gene expression ratios does not replace standard diagnostic protocols, but may be an additional tool for optimized diagnostic process. This approach will be valuable to minimize errors and personalize therapeutic strategies. The last one is critical for prognosis.
Journal
|
SOX2
|
IDH wild-type
1m
A Rare Association of Reactive Retinal Astrocytic Tumor With Chronic Rhegmatogenous Retinal Detachment. (PubMed, Retin Cases Brief Rep)
This report describes a rare association between occult RRAT and chronic RRD in an elderly patient. Histopathologic examination of such tumors is essential for accurate diagnosis while surgical management must be tailored to tumor size, location, and associated complications.
Journal
|
CD163 (CD163 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • GFAP (Glial Fibrillary Acidic Protein)
1m
A congenital infant-type hemispheric glioma case with EML4::ALK fusion. (PubMed, Childs Nerv Syst)
She is now 7 years old and doing well with no recurrence. To our knowledge, this is the first report of a congenital intraventricular tumor with EML4::ALK fusion.
Journal
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • NTRK (Neurotrophic receptor tyrosine kinase)
|
ALK fusion